Clinical Report: Metabolic Modulation and Immune Suppressive Roles of Lipid-Associated Macrophages in Pancreatic Ductal Adenocarcinoma

Overview

Lipid-associated macrophages (LAMs) in pancreatic ductal adenocarcinoma (PDAC) exhibit distinct metabolic reprogramming that contributes to immune evasion.

Background

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a low five-year survival rate, primarily due to its immunosuppressive tumor microenvironment. Tumor-associated macrophages (TAMs), particularly LAMs, play a significant role in this environment, driving immune evasion.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

• LAMs are characterized by co-expression of TREM2, APOE, CD9, and lipid-handling genes.
• Accumulation of LAMs correlates with poor prognosis in PDAC patients.
• LAMs undergo metabolic rewiring involving CD36-mediated lipid uptake and dysregulated cholesterol efflux.
• They suppress CD8+ T cells and NK cells, contributing to the immunosuppressive tumor microenvironment.

Clinical Implications

The identification of LAMs as a distinct macrophage subpopulation in PDAC suggests they may serve as a therapeutic target.

Conclusion

LAMs represent a significant factor in the immunosuppressive landscape of PDAC.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Fatty Acid Metabolism and Lipid Channeling in Macrophages: Mechanisms of Inflammation, Resolution, and Lipotoxicity
2. Frontiers in Immunology, 2026 -- Metabolic reprogramming of cholesterol biosynthesis drives macrophage-mediated immune suppression in HPV-negative cervical adenocarcinoma
3. Journal of Gastroenterology, 2022 -- Exploiting Autophagy as a Therapeutic Approach for Pancreatic Cancer Management
4. Frontiers in Immunology — Immunomodulatory effects of synthetic antimicrobial peptides on LPS-induced inflammatory responses in THP-1 macrophages
5. NCCN Pancreatic Adenocarcinoma Guidelines
6. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer
7. Checking your browser - reCAPTCHA
8. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study - PMC
9. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial | Nature Medicine
10. Frontiers | Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma
11. Single-cell spatial transcriptional profiling of pancreatic ductal adenocarcinoma uncovers key immune-modulating and pro-metastatic mechanisms - ScienceDirect
12. The RASSF1C-HIF-1α axis drives macrophage lipid metabolism to promote pancreatic cancer
13. Targeting tumor-associated macrophages in pancreatic cancer - ScienceDirect
14. Single‐Cell RNA‐Seq Combined With Bulk RNA‐Seq Revealed the Involvement of Pancreatic Cancer Tissue‐Resident Macrophages in Tumour Progression and the Immunotherapy Response - Wu - 2026 - Journal of Cellular and Molecular Medicine - Wiley Online Library